Rosuvastatin - A highly effective new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor: Review of clinical trial data at 10-40 mg doses in dyslipidemic patients

Tools

Item Type:	Review
Title:	Rosuvastatin - A highly effective new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor: Review of clinical trial data at 10-40 mg doses in dyslipidemic patients
Creators Name:	Schuster, H.
Abstract:	Rosuvastatin (Crestor®; licensed to AstraZeneca, Macclesfield, UK from Shionogi, Osaka, Japan) is a new statin with pharmacologic characteristics that translate into selectivity of effect in hepatic cells and enhanced potency in 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibition. It is approved for use at doses of 10–40 mg once daily to reduce low-density lipoprotein (LDL) cholesterol, increase high-density lipoprotein (HDL) cholesterol and improve other lipid measures in dyslipidemic patients. In a dose-ranging study in mild/moderate hypercholesterolemia, rosuvastatin reduced LDL cholesterol by 52–63% at 10–40 mg. Rosuvastatin 10 mg reduces LDL cholesterol significantly more than atorvastatin 10 mg, simvastatin 10–40 mg and pravastatin 10–40 mg, and enables significantly more patients to achieve National Cholesterol Education Program and Joint European Societies LDL cholesterol goals compared with each of these statins. Rosuvastatin also produces marked elevations in HDL cholesterol and maintains this effect across the dose range. Rosuvastatin favorably modifies triglycerides, LDL cholesterol and other lipid measures in patients with hypertriglyceridemia or mixed dyslipidemia, including diabetic patients, and may constitute a monotherapy option for many such patients. Rosuvastatin is well tolerated when used alone or in combination, exhibiting a safety profile similar to that of other available statins. Rosuvastatin offers considerable advantages for use in routine clinical practice.
Keywords:	Clinical Trials as Topic, Drug Administration Schedule, Drug Dose-Response Relationship, Fluorobenzenes, Follow-Up Studies, HDL Cholesterol, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Hyperlipidemias, LDL Cholesterol, Pyrimidines, Rosuvastatin Calcium, Sulfonamides, Treatment Outcome
Source:	Cardiology
ISSN:	0008-6312
Volume:	99
Number:	3
Page Range:	126-139
Date:	June 2003
Official Publication:	https://doi.org/10.1159/000070669
PubMed:	View item in PubMed

Repository Staff Only: item control page